BLCO
HealthcareBausch + Lomb Corporation · Medical - Instruments & Supplies · $6B
What is Bausch + Lomb Corporation?
Bausch + Lomb is a globally recognized eye health company offering products across contact lenses, ophthalmic pharmaceuticals, and surgical equipment. Headquartered in Vaughan, Canada, the company serves patients and practitioners in markets around the world.
The company generates revenue across three business segments. Vision Care and Consumer Health Care covers contact lenses in various wearing modalities, lens care solutions, and over-the-counter eye drops. The Ophthalmic Pharmaceuticals segment markets both proprietary and generic treatments for conditions like glaucoma and retinal disease. The Surgical segment supplies tools, intraocular lenses, and phacoemulsification systems used in cataract and vitreoretinal procedures.
Bausch + Lomb's roots trace back to 1853, though its current corporate structure was established in 2022 and is headquartered in Vaughan, Canada.
- Daily disposable and frequent-replacement contact lenses
- Over-the-counter dry eye drops and eye vitamins
- Prescription ophthalmic pharmaceuticals for glaucoma and retinal disease
- Surgical instruments and intraocular lens delivery systems
- Phacoemulsification equipment for cataract procedures
Is BLCO a Good Stock to Buy?
UQS Score rates BLCO as Below Average overall.
Among the five pillars, Valuation stands out as the relative bright spot, suggesting the market may already be pricing in many of the company's current challenges. Growth registers as Neutral, meaning the business is not contracting but has not yet demonstrated the kind of expansion that would shift the overall profile.
Quality, Moat, and Risk all carry Weak ratings — a combination that signals thin competitive insulation, constrained earnings quality, and meaningful balance-sheet or operational vulnerabilities that investors should weigh carefully.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BLCO pay dividends?
No — Bausch + Lomb Corporation does not currently pay a dividend.
BLCO does not currently pay a dividend. For a company navigating a complex post-spinoff capital structure and investing in product development across three distinct segments, retaining cash rather than distributing it is a common strategic choice. Income-focused investors should factor this into their portfolio planning.
When does BLCO report earnings?
Bausch + Lomb reports earnings on a quarterly cadence, consistent with standard practice for US- and Canada-listed equities.
Across recent reporting periods, the company has faced pressure on profitability metrics even as its diversified segment structure provides some revenue stability. Surgical and pharmaceutical contributions can shift meaningfully quarter to quarter based on procedure volumes and generic competition.
For the most recent quarter's results and guidance commentary, visit Bausch + Lomb's official investor relations page.
BLCO Price History
-5.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Bausch + Lomb Corporation?
Based on Bausch + Lomb Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BLCO Long-term Outlook
The fundamental outlook for BLCO is mixed. A Neutral Growth pillar suggests the business can sustain modest top-line progress, supported by aging demographics driving demand for eye care globally. However, Weak Quality and Risk ratings indicate that translating revenue into durable earnings remains a challenge. The relatively Good Valuation pillar means downside may be partially cushioned, but meaningful re-rating would likely require demonstrated improvement in profitability and competitive positioning.
Growth drivers
- Aging global population increasing demand for cataract surgery and dry-eye treatments
- Expansion of the ophthalmic pharmaceutical portfolio into new therapeutic areas
- Growing contact lens adoption in emerging markets
Key risks
- Generic pharmaceutical competition eroding pricing power in the Ophthalmic segment
- High debt load from the corporate spinoff constraining financial flexibility
- Execution risk across three distinct business segments with different competitive dynamics
BLCO vs Peers
BLCO operates in a competitive healthcare landscape alongside diversified medical technology and life science companies.
Teleflex focuses on single-use medical devices across multiple clinical settings, giving it broader procedural exposure beyond ophthalmology.
Avantor serves biopharma and advanced technology customers with materials and consumables, operating in a different supply-chain niche than eye health.
Repligen specializes in bioprocessing technologies for biologics manufacturing, making it a pure-play on the biopharma production supply chain rather than consumer eye care.
Frequently Asked Questions
What does Bausch + Lomb do?
Bausch + Lomb is an eye health company with three segments: Vision Care and Consumer Health Care (contact lenses, eye drops, vitamins), Ophthalmic Pharmaceuticals (prescription treatments for glaucoma and retinal disease), and Surgical (cataract and vitreoretinal tools and intraocular lenses). It serves patients and eye care professionals worldwide.
Does BLCO pay dividends?
No, BLCO does not currently pay a dividend. The company is focused on managing its capital structure following its corporate spinoff and investing across its three business segments. Investors seeking regular income should note this absence when evaluating the stock.
When does BLCO report earnings?
Bausch + Lomb reports on a quarterly cadence, as is standard for publicly listed companies. For confirmed dates and the most recent results, check the investor relations section of the company's official website.
Is BLCO a good stock to buy?
UQS Score rates BLCO as Below Average, reflecting Weak readings across Quality, Moat, and Risk pillars. The Valuation pillar is the relative strength. Whether that profile suits your investment approach depends on your risk tolerance and time horizon — the full pillar breakdown is available to Pro members.
Is BLCO overvalued?
The UQS Valuation pillar for BLCO is rated Good, suggesting the current market price is not stretched relative to fundamentals. However, valuation alone does not determine investment merit — the Weak Quality and Risk ratings are important context for any valuation assessment.
How does BLCO compare to its competitors?
BLCO is a focused eye health company, while peers like Teleflex and Avantor operate across broader medical device or life science supply-chain markets. Repligen is concentrated in bioprocessing. BLCO's differentiation lies in its end-to-end eye care portfolio, though its UQS profile currently trails what stronger-rated healthcare peers demonstrate.
What is BLCO's market cap bracket?
BLCO is classified as a mid-cap company. This places it in a tier that typically offers more liquidity than small-caps but less scale and financial resilience than large- or mega-cap healthcare peers.
Who founded Bausch + Lomb?
The Bausch + Lomb brand traces its origins to 1853, founded by John Jacob Bausch and Henry Lomb. The current publicly traded entity, Bausch + Lomb Corporation, was established in 2022 as a spinoff. Full historical context is widely available through the company's official communications.
Is BLCO a long-term quality investment?
From a long-term quality perspective, BLCO's UQS profile raises caution. Weak ratings in Quality, Moat, and Risk suggest the business has not yet established the durable competitive advantages and earnings consistency typically associated with strong long-term compounders. The Neutral Growth and Good Valuation pillars offer some balance, but the overall picture warrants careful monitoring.
What is the main competitive advantage of Bausch + Lomb?
Bausch + Lomb benefits from a well-recognized brand in eye care and a diversified product portfolio spanning consumer, pharmaceutical, and surgical categories. However, the UQS Moat pillar is rated Weak, indicating that these advantages have not yet translated into the kind of durable pricing power or switching costs seen in higher-rated peers.
What sector does BLCO belong to?
BLCO operates in the Healthcare sector, specifically within the eye health and ophthalmic products space. It competes across consumer health, specialty pharmaceuticals, and medical devices — giving it exposure to multiple sub-segments of healthcare spending.
Unlock Full BLCO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores for all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare BLCO against sector peers side by side
- ✓See the full Risk and Moat breakdown in detail
- ✓Track UQS Score changes over time
- ✓Get the complete analyst-style quality view
Pro Analysis
BLCO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 42.7 | 13.5 | 34.0 | 42.2 | 68.5 | 81.0 | -0.1 |
| May 22, 2026 | 42.8 | 13.5 | 34.0 | 42.2 | 68.5 | 81.3 | 0.0 |
| May 20, 2026 | 42.8 | 13.5 | 34.0 | 42.2 | 68.5 | 81.5 | +0.1 |
| May 17, 2026 | 42.7 | 13.5 | 34.0 | 42.2 | 68.5 | 80.9 | -0.1 |
| May 16, 2026 | 42.8 | 13.5 | 34.0 | 42.2 | 68.5 | 81.7 | -0.2 |
| May 14, 2026 | 43.0 | 13.5 | 34.0 | 42.2 | 68.5 | 82.4 | -0.2 |
| May 12, 2026 | 43.2 | 13.5 | 34.0 | 42.2 | 68.5 | 84.1 | 0.0 |
| May 11, 2026 | 43.2 | 13.5 | 34.0 | 42.2 | 68.5 | 83.8 | +1.9 |
| May 10, 2026 | 41.3 | 6.2 | 34.0 | 42.2 | 68.5 | 83.8 | -1.9 |
| May 8, 2026 | 43.2 | 13.5 | 34.0 | 42.2 | 68.5 | 83.7 | -0.1 |
BLCO — Pillar Breakdown
Quality
— 13.5/100 (25%)Bausch + Lomb Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 42.2/100 (20%)Bausch + Lomb Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 68.5/100 (15%)Bausch + Lomb Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 82.2/100 (15%)Bausch + Lomb Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 34/100 (25%)Bausch + Lomb Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BLCO.
Score Composition
Financial Data
More Stock Analysis
How is the BLCO UQS Score Calculated?
The UQS (Unified Quality Score) for Bausch + Lomb Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bausch + Lomb Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bausch + Lomb Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.